Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groups Both of Moderna’s COVID-19 vaccines for the ...

Will a hantavirus outbreak offset the regulatory risks weighing on Moderna stock? The path to recovery is far from certain.

Shares of Moderna ( MRNA) were up nearly 7% in recent trading, following a 12% jump Friday, after Bloomberg reported the ...

Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close ...

Moderna announced this weekend that the Food and Drug Administration approved its lower-dose Covid-19 vaccine for adults 65 and older, as well as people ages 12 to 64 with at least one medical ...

Moderna shares jump as it reveals it has been researching vaccines against hantaviruses - The hantavirus outbreak on the MV ...

Moderna's early hantavirus vaccine research has boosted stock price, reflecting market interest. The vaccine is in initial ...

Marjorie Taylor Greene and other conservative commentators have claimed that Moderna is developing a hantavirus mRNA vaccine.

An mRNA-based flu shot could make a huge difference in flu prevention, allowing scientists to pick a better strain match.

After a large trial showed stronger protection, regulators are weighing whether Moderna’s mRNA vaccine could become a U.S.

Inovio Pharmaceuticals and Novavax stocks pare back earlier gains as the rally loses enthusiasm.

Moderna (NASDAQ:MRNA) shares climbed 10% on Thursday as concerns mounted over a hantavirus outbreak connected to a cruise ship.